natgillin/translations-raw huggingface dataset:
Bolnik mora jemati dve 10 mg filmsko obloženi tableti (20 mg) na dan.
The patient should take one 20 mg film-coated tablet (20 mg) per day for 7 days.
Ena tableta vsebuje 20 mg memantinijevega klorida, kar ustreza 16,62 mg memantina.
Each 20 mg tablet contains 20 mg of memantine hydrochloride equivalent to 16.62 mg memantine.
Ena tableta vsebuje 10 mg memantinijevega klorida, kar ustreza 8,31 mg memantina.
Each 10 mg tablet contains 10 mg of memantine hydrochloride equivalent to 8.31 mg memantine.
s študijami zdravljenja v monoterapiji ter študijami bolnikov, ki so prejemali stabilni odmerek zaviralcev acetilholinesteraze), je pokazala statistično značilen učinek v korist zdravljenja z memantinom pri spoznavnih funkcijah ter globalnih in funkcionalnih področjih.
A meta-analysis of patients with moderate to severe Alzheimer's disease (MMSE total scores < 20) from the six phase III, placebo-controlled, 6-month studies (including monotherapy studies and studies with patients on a stable dose of acetylcholinesterase inhibitors) showed that there was a statistically significant effect in favour of memantine treatment for the cognitive, global, and functional domains.
Splošne težave in spremembe na mestu aplikacije
General disorders and administration site conditions
Eesti Sandoz d.d. Estonia Tel: + 372 6652405
Estonia Tel: + 372 6652405
50 filmsko obloženih tablet.
Film-coated tablet.
Memantin ni bil teratogen pri podganah in zajcih,
Memantine was not teratogenic in rats and rabbits, even at maternally toxic doses, and no adverse events of memantine were noted on fertility.
NMDA in tako izboljša prenos živčnih
Memantine LEK acts on these NMDA-receptors improving the transmission of nerve signals and the memory.
EU/1/13/826 /007 28 filmsko obloženih tablet EU/1/13/826 /008 30 filmsko obloženih tablet EU/1/13/826 /009 42 filmsko obloženih tablet EU/1/13/826 /010 56 filmsko obloženih tablet EU/1/13/826 /011 98 filmsko obloženih tablet EU/1/13/826 /015 100 filmsko obloženih tablet
EU/1/13/826 /007 28 film-coated tablets EU/1/13/826 /008 30 film-coated tablets EU/1/13/826 /009 42 film-coated tablets EU/1/13/826 /010 56 film-coated tablets EU/1/13/826 /011 98 film-coated tablets EU/1/13/826 /015 100 film-coated tablets
izmed neželenih učinkov, se posvetujte z zdravnikom ali farmacevtom.
If you get any side effects, talk to your doctor or pharmacist.
OZNAČEVANJE IN NAVODILO ZA UPORABO
ANNEX III LABELLING AND PACKAGE LEAFLET
Redno posodobljena poročila o varnosti zdravila (PSUR) Zahteve za predložitev rednih posodobljenih poročil o varnosti zdravila za to zdravilo
• Periodic safety update reports
Sorazmerno veliki čezmerni odmerki (200 mg dnevno oziroma 105 mg dnevno, tri dni)
Relative large overdoses (200 mg and 105 mg/day for 3 days, respectively) have been associated with either only symptoms of tiredness, weakness and/or diarrhoea or no symptoms.
6.6 Posebni varnostni ukrepi za odstranjevanje Ni posebnih zahtev.
6.6 Special precautions for disposal
Ni znano, ali
Common Not known
Bolnik je okreval brez
The patient recovered without permanent sequelae.
Čeprav vzročna povezanost ni bila dokazana, je pri bolnikih, ki se sočasno zdravijo
Although no causal relationship has been established, close monitoring of prothrombin time or INR is advisable for patients concomitantly treated with oral anticoagulants.
Neznana pogostnost (pogostosti ni mogoče oceniti iz razpoložljivih podatkov):
Not known (frequency cannot be estimated from the available data): • Inflammation of the pancreas, inflammation of the liver (hepatitis) and psychotic reactions
POSEBNI VARNOSTNI UKREPI
SPECIAL STORAGE CONDITIONS
Pred začetkom jemanja zdravila Memantine LEK se posvetujte z zdravnikom ali
Talk to your doctor or pharmacist before taking Memantine LEK
PRETISNI OMOT
Dose titration
Lek Pharmaceuticals d.d. Tel: + 386 1 580 3327
Tel: + 386 1 580 3327
Obloga tablete polivinilalkohol makrogol 3350 titanov dioksid (E 171)
Polyvinyl alcohol Macrogol 3350
Pri drugi študiji zdravljenja v monoterapiji pri blagi do zmerni Alzheimerjevi bolezni (skupna ocena KPSS ob vključitvi 11 do 23 točk), v katero je bilo zajetih in naključno razdeljenih 470 bolnikov.
In another monotherapy study in mild to moderate Alzheimer's disease a total of 470 patients (MMSE total scores at baseline of 11-23) were randomised.
Kako deluje zdravilo Memantin LEK
How does Memantine LEK work
KLINIČNI PODATKI
CLINICAL PARTICULARS
Vrsta ovojnine in vsebina
6.5 Nature and contents of container
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER FOR TABLETS
povzročil nastanek vakuol in nekrozo v nevronih (Olneyeve lezije), vendar le pri odmerkih, ki dajo zelo visoko maksimalno plazemsko koncentracijo.
In short term studies in rats, memantine like other NMDA-antagonists have induced neuronal vacuolisation and necrosis (Olney lesions) only after doses leading to very high peak serum concentrations.
België/Belgique/Belgien
België/Belgique/Belgien Sandoz n.v./s.a.
Seznam neželenih učinkov v preglednici
Tabulated list of adverse reactions
Ob sočasni uporabi memantina in hidroklorotiazida (HCT) oziroma zdravil, ki vsebujejo HCT, lahko pride do zmanjšanja serumske koncentracije HCT.
• There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when memantine is coadministered with HCT or any combination with HCT.
ZA TABLETE
Tablet coat
Podatkov o uporabi memantina pri bolnikih
No data on the use of memantine in patients with severe hepatic impairment are available.
Odmerek
Dyspnoea
NAČIN IZDAJANJA ZDRAVILA
PHARMACEUTICAL FORM
Navodilo za uporabo Memantin LEK 10 mg filmsko obložene tablete Memantin LEK 20 mg filmsko obložene tablete memantinijev klorid
Package leaflet: Information for the user Memantine LEK 10 mg film-coated tablets Memantine LEK 20 mg film-coated tablets memantine hydrochloride
Sandoz s.r.o. Tel: + +420 225 775 111
Tel: + +420 225 775 111
Ena filmsko obložena tableta vsebuje 20 mg memantinijevega klorida, kar ustreza 16,62 mg memantina.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 20 mg of memantine hydrochloride equivalent to 16.62 mg memantine.
Dojenje
Dose
CIBIC-plus (vtis sprememb na podlagi kliničnega intervjuja (CIBIC- clinician's interview based impression of change)), p=0,025; po lestvici ADCS-ADLsev (vprašalnik vsakodnevnih aktivnosti (ADCS-ADLsev-Alzheimer's disease cooperative study - activities of daily living)), p=0,003; testi po SIB (sklop
p=0.025; Alzheimer's disease cooperative study - activities of daily living (ADCS-ADLsev): p=0.003; severe impairment battery (SIB): p=0.002).
Glejte poglavje
- Keep this leaflet.
Ena filmsko obložena tableta vsebuje 10 mg memantinijevega klorida, kar ustreza 8,31 mg memantina.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 10 mg of memantine hydrochloride equivalent to 8.31 mg memantine.
teden (15.-21. dan): Bolnik mora sedem dni jemati eno 15 mg filmsko obloženo tableto na dan.
Week 3 (day 15-21): The patient should take one and a half 10 mg film-coated tablet (15 mg) per day for 7 days.
V šudijah na miših in podganah, ki so potekale celo življenjsko dobo, niso opazili karcinogenosti.
There was no evidence of any carcinogenicity in life long studies in mice and rats.
Učinkovina je memantinijev klorid.
• The active substance is memantine hydrochloride.
teden (1.-7. dan): Bolnik mora sedem dni jemati eno 5 mg filmsko obloženo tableto na dan.
Week 1 (day 1-7): The patient should take half a 10 mg film-coated tablet (5 mg) per day for 7 days.
Memantin LEK 20 mg filmsko obložene tablete memantinijev klorid
NAME OF THE MEDICINAL PRODUCT Memantine LEK 20 mg film-coated tablets memantine hydrochloride
Klinične študije V temeljno klinično študijo je bilo vključenih 252 bolnikov z zmerno do hudo Alzheimerjevo boleznijo, ki so ob vključitvi pri kratkem preizkusu spoznavnih sposobnosti (MMSE - mini-mental state examination) dosegli 3-14 točk. Po 6-mesečni monoterapiji z memantinom se je pri opazovanih bolnikih pokazalo
A pivotal monotherapy study in a population of patients suffering from moderate to severe Alzheimer's disease (mini mental state examination (MMSE) total scores at baseline of 3 - 14) included a total of 252 outpatients.
s kationskimi amfifilnimi lastnostmi.
This effect is known from other active substances with cationic amphiphilic properties.
Bolezni jeter, žolčnika in žolčevodov Pogosti zvišane vrednosti testov jetrne funkcije
Elevated liver function test Hepatitis
Τηλ: + 357 - 25372425
P.T.Hadjigeorgiou Co Ltd Τηλ: + 357 - 25372425
PODATKI NA ZUNANJI OVOJNINI ZUNANJA OVOJNINA
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
UPORABE ZDRAVILA Pred uporabo preberite navodilo za uporabo.
METHOD AND ROUTE(S) OF ADMINISTRATION Read the package leaflet before use.
Memantin LEK 20 mg filmsko obložene tablete
NAME OF THE MEDICINAL PRODUCT Memantine LEK 20 mg film-coated tablets
Plodnost
Fertility
Memantin LEK 10 mg filmsko obložene tablete memantinijev klorid
NAME OF THE MEDICINAL PRODUCT Memantine LEK 10 mg film-coated tablets memantine hydrochloride
Prenašanje in odmerjanje memantina je treba redno ocenjevati,
The tolerance and dosing of memantine should be reassessed on a regular basis, preferably within three months after start of treatment.
so pri glodalcih in psih, ne pa tudi pri opicah, občasno opazili spremembe na očeh.
Ocular changes were inconsistently observed in repeat dose toxicity studies in rodents and dogs, but not in monkeys.
s plodnostjo pri moških ali ženskah niso opazili.
No adverse reactions of memantine were noted on male and female fertility.
spojin v krvi zaradi renalne disfunkcije (slabega delovanja ledvic)) ali če imate hudo vnetje sečil (strukture po kateri
You should inform your doctor if you have recently changed or intend to change your diet substantially (e.g. from normal diet to strict vegetarian diet) or if you are suffering from states of renal tubulary acidosis (RTA, an excess of acid-forming substances in the blood due to renal dysfunction (poor kidney function)) or severe infections of the urinary tract (structure that carries urine), as your doctor may need to adjust the dose of your medicine.
Memantin se izloča na monoeksponentni način
Memantine is eliminated in a monoexponential manner with a terminal t½ of 60 to100 hours.
ZUNANJA OVOJNINA
OUTER PACKING
Zdravilo shranjujte nedosegljivo otrokom!
Keep this medicine out of the sight and reach of children.
Način uporabe
Oral use.
Pogosti hipertenzija
Drug hypersensitivity
Pogosti motnje ravnotežja
Dizziness Balance disorders Gait abnormal Seizures
tedna dalje (22.-28. dan): Bolnik mora jemati eno 20 mg filmsko obloženo tableto na dan 7 dni.
Week 2 (day 8-14): The patient should take one 10 mg film-coated tablet (10 mg) per day for 7 days.
Če opazite katerega koli
What is in this leaflet
Če ste pozabili vzeti zdravilo Memantin LEK
Do not take Memantine LEK
Ledvična okvara
Renal impairment
ZA PROMET Pharmathen S.A.
NAME OF THE MARKETING AUTHORISATION HOLDER Pharmathen S.A.
Zdravilo Memantine LEK je namenjeno za peroralno uporabo.Zdravilo Memantin LEK je treba jemati enkrat dnevno
Memantine LEK should be administered once a day and should be taken at the same time every day.
SEZNAM POMOŽNIH SNOVI
GENERAL CLASSIFICATION FOR SUPPLY
B. NAVODILO ZA UPORABO
B. PACKAGE LEAFLET
filmsko obložena tableta 28 filmsko obloženih tablet.
28 film-coated tablets 30 film-coated tablets 42 film-coated tablets 56 film-coated tablets 98 film-coated tablets 100 film-coated tablets
s hudo jetrno okvaro ni na voljo.
No specific antidote for intoxication or overdose is available.
POSEBNA NAVODILA
Special populations
Zdravilo Memantin LEK jemljite tako dolgo, kot vam pomaga in se ne pojavijo neželeni učinki, ki jih ne prenašate.
Continue to take Memantine LEK as long as it is of benefit to you.
Izločanje Memantin se izloča na monoeksponentni način
Memantine is eliminated in a monoexponential manner with a terminal t½ of 60 to 100 hours.
IZDELOVALCI ODGOVORNI
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE
Pogostost
Common
• epileptični napadi
• if you have a history of epileptic seizures.
s centralnim živčnim sistemom (zmedenost, dremavost, zaspanost, vrtoglavica,
In the overdose cases below 140 mg or unknown dose the patients revealed symptoms from central nervous system (confusion, drowsiness, somnolence, vertigo, agitation, aggression, hallucination, and gait disturbance) and/or of gastrointestinal origin (vomiting and diarrhoea).
Z VARNO IN UČINKOVITO UPORABO
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Neželeni učinek
Adverse reaction
Резултат от процедурата по член 29 от Директива 2001/83/EО
Outcome of a procedure under Article 29 of Directive 2001/83/EC as amended
Европейската комисия издава решение на 08 октомври 2012 г.
The European Commission issued a decision on 08 October 2012.
08 октомври 2012 г.
08 October 2012
EMA/476365/2012 Рев. 1 EMEA/H/A-29/1332
EMA/476365/2012 rev1 EMEA/H/A-29/1332
Какви за заключенията на CHMP?
What are the conclusions of the CHMP?
Освен това съществуват съмнения относно методологията, използвана за анализ на in vitro резултатите.
In addition, there were concerns over the methodology used to analyse these in vitro results.
Въпреки това държавите членки не успяват да стигнат до съгласие и на 23 февруари 2012 г. испанската регулаторна агенция отнася въпроса към CHMP за арбитраж.
However, the Member States were not able to reach an agreement, and the Spanish medicines regulatory agency referred the matter to the CHMP for arbitration on 23 February 2012.
Това означава, че то е подобно на вече разрешено в ЕС „референтно лекарство“, което съдържа същото активно вещество, но което се прилага чрез използване на друг вид изделие за спрей за нос.
This means that it is similar to a ‘reference medicine' already authorised in the EU that contains the same active substance, but which is given using a different type of nasal spray device.
Поради това испанската агенция счита, че резултатите от in vitro проучванията не могат да се използват, за да се предвиди колко добре би действало лекарството при пациентите.
The Spanish agency therefore considered that the results from the in vitro studies could not be used to predict how well the medicine would work in patients.
Той действа чрез прикрепване към рецепторите на различни типове имунни клетки, като води до намаляване на отделянето на вещества, които са включени в процеса на възпаление, и по този начин намалява симптомите на алергия.
It works by attaching to receptors in various types of immune cells, leading to a reduction in the release of substances that are involved in the inflammation process, and thereby reducing the symptoms of allergy.
Въз основа на наличните към момента данни и научната дискусия в Комитета, CHMP признава някои от опасенията на испанската агенция, но заключава, че като цяло е доказано в задоволителна степен, че като се имат предвид всички in vitro данни, възможните различки между Mometasone Furoate Sandoz и референтното лекарство не биха могли да засегнат съотношението полза/риск.
Based on the evaluation of the currently available data and the scientific discussion within the Committee, the CHMP recognised some of the concerns of the Spanish agency, but concluded that overall it was sufficiently demonstrated that possible differences between Mometasone Furoate Sandoz and the reference medicine would not affect the benefit-risk balance of the product, taking into account all the in vitro data.
Европейската агенция по лекарствата завършва процедура по арбитраж след несъгласие между държавите - членки на Европейския съюз (ЕС), по отношение на разрешаването на лекарството Mometasone Furoate Sandoz.
On 19 July 2012, the European Medicines Agency completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Mometasone Furoate Sandoz.
Използва се за превенция на умерени до тежки симптоми на сезонен алергичен ринит преди да започнат сезонните полени.
It is also used to prevent moderate to severe symptoms of seasonal allergic rhinitis before the pollen seasons starts.
Mometasone Furoate Sandoz се използва при възрастни и деца на възраст от шест години за лечение на симптомите на сезонен алергичен или постоянен ринит (възпаление на носните пътища, причинено от алергия като сенна хрема или което се появява през цялата година).
Mometasone Furoate Sandoz is used in adults and children from six years of age to treat the symptoms of seasonal allergic or perennial rhinitis (inflammation of the nasal passages caused by an allergy such as hay fever, or which occurs throughout the year).
Поради това CHMP заключава, че ползите от Mometasone Furoate Sandoz надвишават рисковете и препоръчва издаване на разрешение за употреба в засегнатите държави членки.
The CHMP therefore concluded that the benefits of Mometasone Furoate Sandoz outweigh its risks and recommended that the marketing authorisation be granted in the concerned Member States.
Sandoz B.V. внася заявление за Mometasone Furoate Sandoz в датската регулаторна агенция за децентрализирана процедура.
Sandoz B.V. submitted an application for Mometasone Furoate Sandoz to the Dutch medicines regulatory agency for a decentralised procedure.
Активното вещество, мометазон фуроат, принадлежи към групата на „глюкокортикоидите“.
The active substance, mometasone furoate, belongs to the group ‘glucocorticoids'.
(„засегнати държави членки“, в този случай Белгия, Чешката република, Дания, Естония, Финландия, Франция, Германия, Гърция, Унгария, Италия, Люксембург, Полша, Португалия, Румъния, Словакия, Словения, Испания, Швеция и
This is a procedure where one Member State (the ‘reference Member State', in this instance the Netherlands) assesses a medicine with a view to granting a marketing authorisation that will be valid in this country as well as in other Member States (the ‘concerned Member States', in this instance Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Luxembourg, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom, as well as Norway).
Причините за сезирането са съмнения относно типа на in vitro проучванията (експериментални), проведени за да покажат, че Mometasone Furoate Sandoz е сравним с Nasonex (това, че той води до същите нива на активното вещество в носа както Nasonex).
The grounds for the referral were concerns over the type of in vitro (experimental) studies carried out to demonstrate that Mometasone Furoate Sandoz is comparable to Nasonex (that it produces the same levels of the active substance in the nose as Nasonex).
„Референтното лекарство'' за Mometasone Furoate Sandoz се нарича Nasonex.
The ‘reference medicine' for Mometasone Furoate Sandoz is called Nasonex.
Освен това той се използва при възрастни за лечение на симптоми на назални полипи (израстъци по лигавицата на носа).
In addition, it is used in adults to treat the symptoms of nasal polyps (growths in the lining of the nose).
Белгия, Чешката република, Дания, Естония, Финландия, Франция, Германия, Гърция, Унгария, Италия, Люксембург, Полша, Португалия, Румъния, Словакия, Словения, Испания, Швеция и Обединеното кралство, както и Норвегия.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Mometasone Furoate Sandoz outweigh its risks, and that the marketing authorisation can be granted in the Netherlands and in the following Member States of the EU: Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Luxembourg, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom, as well as Norway.
Mometasone Furoate Sandoz е лекарство, което съдържа активното вещество мометазон фуроат.
Mometasone Furoate Sandoz is a medicine that contains the active substance mometasone furoate.
Какво представлява Mometasone Furoate Sandoz?
What is Mometasone Furoate Sandoz?
Mometasone Furoate Sandoz е „хибридно лекарство“.
Mometasone Furoate Sandoz is a ‘hybrid medicine'.
Наличен е под формата на спрей за нос.
It is available as a nasal spray.
Освен това данните от клинично проучване предоставят допълнително доказателство, че Mometasone Furoate Sandoz спрей за нос действа както Nasonex спрей за нос при пациенти.
Also, data from a clinical study provided additional evidence that Mometasone Furoate Sandoz nasal spray works as well as Nasonex nasal spray in patients.
Обикновено един комплект е достатъчен.
Generally one kit is sufficient.
Може да се използва в следните случаи:
It can be used in the following situations:
Пълният текст на EPAR относно Inductos може да се намери на уебсайта на Агенцията: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The full EPAR for Inductos can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Разработен е план за управление на риска, за да се гарантира, че Inductos се използва възможно най-безопасно.
A risk management plan has been developed to ensure that Inductos is used as safely as possible.
Какви мерки се предприемат, за да се гарантира безопасната и ефективна употреба на Inductos?
What measures are being taken to ensure the safe and effective use of Inductos?
След две години 57% от пациентите, лекувани с Inductos (69 от122), се повлияват от лечението, в сравнение с 59% от пациентите, лекувани с присаждане на кост (78 от 133).
After two years, 57% of the patients treated with Inductos (69 out of 122) had responded to treatment, compared with 59% of the patients treated with a bone graft (78 out of 133).
Inductos трябва да се използва от квалифициран хирург.
Inductos should be used by a qualified surgeon.
Настоящият документ представлява резюме на Европейския публичен оценъчен доклад (EPAR) зa Inductos.
This is a summary of the European public assessment report (EPAR) for Inductos.
Освен това фирмата производител на Inductos ще гарантира, че във всички държави-членки е наличен обучителен материал за здравните специалисти, които се очаква да използват лекарството.
In addition, the company that markets Inductos will make sure that educational material is available in all Member States for all healthcare professionals expected to use the medicine.
За повече информация относно лечението с Inductos прочетете листовката (също част от EPAR) или попитайте Вашия лекар или фармацевт.
For more information about treatment with Inductos, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Inductos се използва при възрастни, които са лекувани в продължение на най-малко шест месеца за болки в гърба, дължащи се на увреден диск, но не са били подложени на операция.
Inductos is used in adults who have been treated for at least six months for back pain due to a damaged disc but have not had an operation.
пациенти с диагноза или лечение на рак,
• patients diagnosed with or being treated for cancer;
Той ще съдържа информация за риска от хетеротопна осификация и за потенциалния риск от медицински грешки и неправилна употреба на Inductos.
This material will include information on the risk of heterotopic ossification and the potential risk of medication errors and incorrect use of Inductos.
След това, ако е необходимо, матрицата се изрязва, за да се коригира размерът преди употреба.
The matrix is then cut, if needed, to the correct size before use.
Въз основа на този план информацията за безопасността е включена в кратката характеристика на продукта и в листовката за Inductos, включително подходящи предпазни мерки за здравните специалисти и пациентите.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Inductos, including the appropriate precautions to be followed by healthcare professionals and patients.
Допълнителна информация за Inductos:
Other information about Inductos
Преди употреба Inductos се приготвя като разтвор, който се нанася върху матрицата и се оставя поне 15 минути (но не повече от два часа).
Inductos is made up into a solution before use, applied to the matrix and left for at least 15 minutes (but no more than two hours).